Literature DB >> 16702894

The status of disulfiram: a half of a century later.

Jesse J Suh1, Helen M Pettinati, Kyle M Kampman, Charles P O'Brien.   

Abstract

For more than 55 years, disulfiram has been approved by the Food and Drug Administration for the treatment of alcohol dependence. It is a unique medication that relies on "psychological threat" to avoid disulfiram-ethanol reactions. This paper reviews the history of disulfiram treatment, the current status of disulfiram treatment, the ensuing developments in disulfiram use in treating various addictions, and future directions. Clinical trials using disulfiram for the treatment of alcohol, cocaine, or co-occurring alcohol + cocaine dependence were included in this review. Disulfiram efficacy studies focusing on supervised, implant, and combination pharmacotherapies were also examined. In clinical trials, disulfiram has demonstrated inconsistent results in helping patients to abstain from alcohol, and patients poorly adhere to a disulfiram-treatment regimen. This has raised questions about disulfiram's practicality in the treatment of alcohol dependence. Recently, however, disulfiram has gained attention as a complementary agent to newer pharmacological medications, such as an opiate antagonist that specifically reduces alcohol craving. One hypothesis is that disulfiram would assist patients in gaining psychological control over drinking when given in conjunction with an opiate antagonist that would act directly on reducing alcohol craving. Preliminary evidence also suggests that disulfiram treatment could be a viable treatment for cocaine dependence because it was shown to reduce cocaine use among nonalcoholic, cocaine-dependent patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702894     DOI: 10.1097/01.jcp.0000222512.25649.08

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  94 in total

1.  New pharmacotherapies for treating the neurobiology of alcohol and drug addiction.

Authors:  Helen M Pettinati; Amanda R Rabinowitz
Journal:  Psychiatry (Edgmont)       Date:  2006-05

2.  Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis.

Authors:  Lina Yao; Peidong Fan; Maria Arolfo; Zhan Jiang; M Foster Olive; Jeff Zablocki; Hai-Ling Sun; Nancy Chu; Jeongrim Lee; Hee-Yong Kim; Kwan Leung; John Shryock; Brent Blackburn; Ivan Diamond
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

Review 3.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

4.  Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster.

Authors:  Josef Frank; Sven Cichon; Jens Treutlein; Monika Ridinger; Manuel Mattheisen; Per Hoffmann; Stefan Herms; Norbert Wodarz; Michael Soyka; Peter Zill; Wolfgang Maier; Rainald Mössner; Wolfgang Gaebel; Norbert Dahmen; Norbert Scherbaum; Christine Schmäl; Michael Steffens; Susanne Lucae; Marcus Ising; Bertram Müller-Myhsok; Markus M Nöthen; Karl Mann; Falk Kiefer; Marcella Rietschel
Journal:  Addict Biol       Date:  2011-10-18       Impact factor: 4.280

5.  A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.

Authors:  Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Hu Xie; Charles Dackis; Amanda R Rabinowitz; Charles P O'Brien
Journal:  Addict Behav       Date:  2007-11-17       Impact factor: 3.913

Review 6.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

7.  Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

Authors:  Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-10-30       Impact factor: 4.530

8.  An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits.

Authors:  Jennie Wei; Triveni Defries; Mia Lozada; Natalie Young; William Huen; Jacqueline Tulsky
Journal:  J Gen Intern Med       Date:  2014-08-05       Impact factor: 5.128

9.  Combination of Disulfiram and Copper-Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer.

Authors:  Yan Chang; Fang Wu; Nil Kanatha Pandey; Lalit Chudal; Meiying Xing; Xiaoli Zhang; Linh Nguyen; Xian Liu; J Ping Liu; Wei Chen; Zui Pan
Journal:  ACS Appl Bio Mater       Date:  2020-09-09

10.  Post-soviet placebos: epistemology and authority in Russian treatments for alcoholism.

Authors:  Eugene Raikhel
Journal:  Cult Med Psychiatry       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.